|
"mok tony s k"的相关文件
显示项目 1-4 / 4 (共1页)
1
每页显示[10|25|50]项目
| 國立臺灣大學 |
2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|
Soria, Jean-Charles; Wu, Yi-Long; Nakagawa, Kazuhiko; Kim, Sang-We; Yang, Jin-Ji; Ahn, Myung-Ju; Wang, Jie; Yang, James Chih-Hsin; Lu, You; Atagi, Shinji; Ponce, Santiago; Lee, Dae Ho; Liu, Yunpeng; Yoh, Kiyotaka; Zhou, Jian-Ying; Shi, Xiaojin; Webster, Alan; Jiang, Haiyi; Mok, Tony S. K.; 楊志新 |
| 國立臺灣大學 |
2014 |
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)
|
Yang, James Chih-Hsin; Wu, Yi-Long; Chan, Valorie; Kurnianda, Johan; Nakagawa, Kazuhiko; Saijo, Nagahiro; Fukuoka, Masahiro; McWalter, Gael; McCormack, Rose; Mok, Tony S. K.; 楊志新 |
| 國立臺灣大學 |
2013 |
Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
|
Yang, James Chih-Hsin; Hirsh, Vera; Schuler, Martin; Yamamoto, Nobuyuki; O'Byrne, Kenneth J.; Mok, Tony S. K.; Zazulina, Victoria; Shahidi, Mehdi; Lungershausen, Juliane; Massey, Dan; Palmer, Michael; Sequist, Lecia V.; 楊志新 |
| 國立臺灣大學 |
2013 |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
|
Wu, Yi-Long; Fukuoka, Masahiro; Mok, Tony S. K.; Saijo, Nagahiro; Thongprasert, Sumitra; Yang, James C. H.; Chu, Da-Tong; Yang, Jin-Ji; Rukazenkov, Yuri; 楊志新 |
显示项目 1-4 / 4 (共1页)
1
每页显示[10|25|50]项目
|
